Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	neurotrophic keratopathy	Recruiting	Phase 3	2025-12-23		NCT05555589

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
ReGenTree, LLC	1

36 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Advance Vision Research Institute	Longmont	United States	1
Aiken Prevención & Cirugía Ocular	Valencia	Spain	1
Azienda Ospedaliero Universitaria Careggi	Florence	Italy	1
Berkeley Eye Center	Sugar Land	United States	5
Cataract & Laser Institute of Southern Oregon	Medford	United States	1
Cleveland Clinic, Cole Eye Institute	Cleveland	United States	2
Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons	Danbury	United States	1
CORE, Inc. / Vita Eye Clinic	Shelby	United States	1
Duke Eye Center	Durham	United States	14
Gabinet Okulistyczny Prof Edward Wylegala	Katowice	Poland	2
Harvard Eye Associates	Laguna Hills	United States	5
Hospital La Arruzafa	Córdoba	Spain	1
Huffman & Huffman, PSC	Lexington	United States	1
IMO Barcelona, Grupo Miranza	Barcelona	Spain	1
Instituto Oftalmológico Fernández-Vega	Oviedo	Spain	1
Loma Linda University Eye Institute	Loma Linda	United States	5
MCOA Eye Care	San Antonio	United States	1
Metropolitan Eye Research and Surgery Institute	Palisades Park	United States	3
Midwest Cornea Associates, LLC.	Carmel	United States	1
Midwest Vision Research Foundation	Chesterfield	United States	4
Montefiore Medical Center	The Bronx	United States	198
Nature Coast Clinical Research	Crystal River	United States	5
Northwestern	Chicago	United States	17
Oculus Research	Raleigh	United States	1
OHSU Casey Eye Institute	Portland	United States	4

Clinical trials